Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies - Université de Tours Accéder directement au contenu
Article Dans Une Revue Liver International Année : 2020

Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies

Résumé

The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B-C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV-HCV bivalent vaccine-bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide.
Fichier principal
Vignette du fichier
Liver-International-Vaccin.pdf (617.76 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04112891 , version 1 (01-06-2023)

Identifiants

Citer

Elodie Beaumont, Benoit Joël Clément, Vanessa Guérin, Lucie Chopin, Emmanuelle Roch, et al.. Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies. Liver International, 2020, 40 (8), pp.1865-1871. ⟨10.1111/liv.14541⟩. ⟨hal-04112891⟩

Collections

UNIV-TOURS
7 Consultations
50 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More